---
title: "Trump threatens NHS with higher drug prices"
description: "Donald Trump is pressuring major pharmaceutical companies, including GSK and AstraZeneca, to lower drug prices for Americans. He suggests that these companies should compensate for the reduced prices "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251061482.md"
published_at: "2025-07-31T20:33:26.000Z"
---

# Trump threatens NHS with higher drug prices

> Donald Trump is pressuring major pharmaceutical companies, including GSK and AstraZeneca, to lower drug prices for Americans. He suggests that these companies should compensate for the reduced prices in the US by increasing prices abroad, posing a potential threat to the NHS.

Donald Trump is pressuring the world’s biggest drug makers to raise prices outside of the US in a threat to the NHS. The US president has written to pharmaceutical companies including Britain’s GSK and AstraZeneca to demand they lower prices for Americans, suggesting they should pay for it by charging higher fees abroad. It raises the threat of hig...

### Related Stocks

- [GSK.UK - GlaxoSmithKline plc](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.US - GSK](https://longbridge.com/en/quote/GSK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GSK Recieves Approval For Exdensur From The European Commission | GSK plc :GSK PLC - EXDENSUR APPROVED BY THE EUROPEAN COMMISSIONGSK PLC - EXDENSUR APPROVED BY THE EUROPEAN COMMISSION | [Link](https://longbridge.com/en/news/276102835.md) |
| GSK Begins Up to GBP450 Million Share Buyback Tranche | GSK Begins Up to GBP450 Million Share Buyback Tranche | [Link](https://longbridge.com/en/news/276103252.md) |
| Exdensur approved in EU for severe asthma and CRSwNP | GSK has received European Commission approval for Exdensur (depemokimab), the first ultra-long-acting biologic for sever | [Link](https://longbridge.com/en/news/276226507.md) |
| Berenberg Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK) | Berenberg Bank analyst Kerry Holford has maintained a Hold rating on GlaxoSmithKline (GSK) with a price target of £20.00 | [Link](https://longbridge.com/en/news/276103203.md) |
| GSK Begins Fourth Tranche Of Up To GBP 0.45 Bln Share Buyback Under GBP 2 Bln Programme | British drug major GSK plc has announced the commencement of the fourth tranche of its £2 billion share buyback program, | [Link](https://longbridge.com/en/news/276103384.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.